Medications For Heart Failure Global Market Report 2025

The medications for the heart failure market size has grown strongly in recent years. It will grow from$10.14 billion in 2024 to $10.9 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth during the historic period can be attributed to factors such as the rising prevalence of cardiovascular diseases, increased diagnosis and awareness, regulatory approvals and support, higher R&D spending on cardiovascular drugs, and the adoption of telemedicine and remote monitoring tools.

The medications for the heart failure market size is expected to see strong growth in the next few years. It will grow to$14.37 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth during the forecast period can be attributed to factors such as the expansion of personalized and precision medicine, the rising global burden of lifestyle diseases, a robust pipeline of combination therapies and fixed-dose formulations, increasing clinical evidence and updated guidelines, and growing urbanization. Key trends in the forecast period include the growth of SGLT2 inhibitors, integration of digital health technologies, the use of remote monitoring tools and AI-driven analytics, a greater focus on HFpEF treatment, and ongoing research and development efforts.

The growing prevalence of cardiovascular diseases is expected to drive the expansion of the heart failure medications market in the coming years. Cardiovascular diseases encompass conditions affecting the heart and blood vessels, often leading to serious problems such as heart attacks and strokes. This rise in cardiovascular diseases is primarily due to sedentary lifestyles, which progressively impair heart and vessel health. As the incidence of these diseases increases, the demand for effective treatments also grows, prompting more investment in heart failure medications. With the condition becoming more common, pharmaceutical companies are focusing on developing and improving therapies to better manage symptoms and enhance patient outcomes. For example, in September 2024, the Heart Failure Society of America (HFSA) reported that approximately 6.7 million Americans aged 20 and older are living with heart failure (HF), a number expected to grow to 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050. Thus, the rising incidence of cardiovascular diseases is a key driver of the heart failure medications market's growth.

Leading companies in the heart failure medication market are focused on developing advanced drugs such as sodium-glucose cotransporter (SGLT) inhibitors, which offer more effective long-term management of heart failure symptoms and complications. An SGLT inhibitor is an advanced drug that targets glucose reabsorption mechanisms, helping to manage heart failure, enhance treatment efficiency, and optimize cardiovascular health. For example, in May 2023, Lexicon Pharmaceuticals, a US-based biopharmaceutical company, launched Inpefa (sotagliflozin), a medication approved by the Food and Drug Administration (FDA). Inpefa is a once-daily oral tablet designed to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. This approval represents a significant achievement for Lexicon, as Inpefa is the first dual SGLT1/SGLT2 inhibitor to be marketed, offering a new treatment option for heart failure patients with various conditions.

In March 2024, Novo Nordisk, a Denmark-based pharmaceutical company, acquired Cardior Pharmaceuticals for $1.112 billion. The acquisition aims to strengthen Novo Nordisk's cardiovascular drug pipeline, particularly with Cardior's lead compound CDR132L, which is currently in phase 2 clinical trials for treating heart failure. Cardior Pharmaceuticals, based in Germany, specializes in researching oligonucleotide-based inhibitors for heart failure treatment.

Major players in the medications for heart failure market are Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals Inc., Steris Pharma, CSPC Pharmaceutical, Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals, Ionis Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Hainan Poly Pharm. Co. Ltd., Addii Biotech, Lunan Pharmaceutical Group, Mylan Laboratories Inc., Neuracle Lifesciences Private Limited, JM Laboratories, and Lexicon Pharmaceuticals.

North America was the largest region in the medications for the heart failure market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in medications for the heart failure report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the medications for the heart failure market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Medications for heart failure are drugs designed to treat and manage heart failure, a condition in which the heart struggles to pump blood effectively to meet the body's needs. These medications help improve heart function, alleviate symptoms, prevent hospitalizations, and enhance survival.

The main drug classes used to treat heart failure include angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics, aldosterone antagonists, angiotensin II receptor blockers (ARBs), and others. ACE inhibitors work by relaxing blood vessels through the inhibition of angiotensin II formation, which helps lower blood pressure and reduce the heart's workload. They are commonly prescribed for both high blood pressure and heart failure. These medications are administered via different routes, such as oral and intravenous, and are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others. They are used in a range of settings, including hospitals, clinics, and more.

The medications for heart failure market research report is one of a series of new reports that provides medications for heart failure market statistics, including the medications for heart failure industry global market size, regional shares, competitors with the medications for heart failure market share, detailed medications for heart failure market segments, market trends, and opportunities, and any further data you may need to thrive in the medications for heart failure industry. This medications for heart failure market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The medications for the heart failure market consist of sales of angiotensin receptor-neprilysin inhibitors, hydralazine and nitrates, ivabradine, and digoxin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.